The objective of the French biotechnology company, Vect-Horus, is to leverage its technology, VECTrans, to facilitate the delivery of drugs into the brain and other organs. For this innovation, the company recently received the Frost & Sullivan 2016 Leadership award, which independently recognizes companies for demonstrating excellence in developing innovative technologies and practices within an industry. We had the chance to meet Alexandre Tokay, the co-founder and CEO.
What is the scientific background of your invention?
Biologicals are an emerging class of medicine with considerable promise to treat neurological disorders like Alzheimer’s disease, stroke and multiple sclerosis. However, the blood-brain barrier (BBB), which prevents most toxic molecules and infectious agents from entering the brain, also heavily restricts the passage of therapeutic products from the blood to the brain following systemic administration. Indeed, an estimated 98% of all active drugs, including peptides, proteins and therapeutic antibodies, are not able to cross the BBB.
One promising strategy for overcoming this barrier to delivering biologicals is the targeting the endogenous receptor-mediated transport (RMT) system that employs vesicular trafficking.